Investment pioneer Samer Choucair confirmed that the radical transformations witnessed by the global healthcare sector, driven by the revolution of GLP-1 drugs designated for treating diabetes and weight management, represent a golden investment opportunity for the Kingdom of Saudi Arabia and the GCC countries. Samer Choucair pointed out that this class of drugs is no longer just a medical innovation, but has turned into a massive economic driver reshaping the investment map in the pharmaceutical and biotechnology industries.
Samer Choucair’s statements come in light of the increase in human stories and personal experiences associated with these drugs, such as those highlighting the challenges of eating disorders and the amazing results of GLP-1 drugs, reflecting the expansion of global and local demand. Samer Choucair explained that this phenomenon intersects directly with the Health Sector Transformation Program in the Kingdom, which focuses on preventive care and combating chronic diseases.
Accelerated market growth and government support
Samer Choucair noted that global expectations indicate the GLP-1 drug market size will reach more than 100 billion dollars by the end of the current decade. In the Saudi market, this sector is witnessing a compound annual growth rate of up to 13%, supported by the goals of Vision 2030 which seeks to localize pharmaceutical industries and achieve self-sufficiency.
Samer Choucair said: “In 2026, investors must look at GLP-1 drugs as a gateway to an integrated investment ecosystem. We are not just talking about a pharmaceutical product, but about opportunities that extend to include local manufacturing, innovation in biotechnology, and supportive digital healthcare solutions. Vision 2030 provides the ideal environment to attract foreign capital and enhance international partnerships in this vital field.”
Strategic investment opportunities in the Kingdom and the Gulf
Samer Choucair identified four main axes for tangible investment opportunities in this sector:
Local manufacturing and international partnerships: Encouraging the establishment of advanced factories to produce these drugs locally, reducing reliance on imports and opening horizons for regional export.
Digital technologies and Healthtech: Increased demand for health monitoring applications, AI systems to monitor side effects, and telemedicine platforms.
Investment in stocks and funds: Benefiting from the listing of global and local pharmaceutical companies on the Saudi Stock Exchange (Tadawul), or through funds supported by the Public Investment Fund (PIF).
Integrated care and health tourism: Investing in comprehensive care programs that combine pharmacological treatment with nutrition and physical activity, enhancing the Kingdom’s position as a destination for medical tourism.
Smart diversification and 2026 trends
Investment pioneer Samer Choucair stressed the need for Gulf investors to move now to restructure their investment portfolios to suit the trends of 2026, emphasizing that relying on traditional sectors alone involves risks in light of the current economic transformation.
Samer Choucair concluded his statement by saying: “Conscious investment in the health sector represents a living model of how to transform health challenges into sustainable economic opportunities. Investors who understand global market dynamics and link them to the goals of Vision 2030 will reap the fruits of strategic diversification. The time is ideal today to enter this promising sector and build a healthy and prosperous future for the Kingdom and the region.”